CFO
KYMR icon

CVA Family Office’s Kymera Therapeutics KYMR Stock Holding History

CVA Family Office’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12
Closed -$568 – 1319
2024
Q3 		$568 Buy
+12
New +$530 ﹤0.01% 1181

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

CVA Family Office's KYMR Position: Q4 2024 in Review

CVA Family Office sold out of Kymera Therapeutics (KYMR) in Q4 2024, closing a stake of 12 shares — an estimated $568 sold.

CVA Family Office first reported a position in KYMR in Q3 2024 and held it in 1 quarter. The position peaked at $568 in Q3 2024. 180 funds tracked by Wall St. Rank hold KYMR as of Q4 2024.

  • CVA Family Office reported no remaining Kymera Therapeutics position as of Q4 2024 after selling out during the quarter.
  • CVA Family Office sold 12 Kymera Therapeutics shares in Q4 2024, an estimated $568.
  • CVA Family Office first reported a position in Kymera Therapeutics in Q3 2024 and held it in 1 quarter.
  • CVA Family Office's Kymera Therapeutics position peaked at $568 in Q3 2024.
  • 180 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q4 2024.

Based on CVA Family Office's 13F filing for Q4 2024, filed 7 Jan 2025.